Table 3.
Variables | Total (N = 100) |
---|---|
Age, years | 35 (27.5–49) |
Sex - n (%) | |
Female Male |
94 (94%) 6 (6%) |
Time of illness (SLE), years | 7.5 (4–13) |
Comorbidities* Hypothyroidism Chronic kidney disease APS† Arterial hypertension Rheumatoid arthritis Sjögren’s syndrome Others‡ |
55 (55%) 15 (15%) 13 (13%) 7 (7%) 7 (7%) 6 (6%) 5 (5%) 20 (20%) |
Associated commitment of SLEǂ | |
Articulate Renal Dermal Hematological Mucocutaneous Pulmonary Neurological Cardiovascular |
74 (74%) 60 (60%) 23 (23%) 21 (21%) 17 (17%) 15 (15%) 15 (15%) 4 (4%) |
Usual treatment of SLE | |
Prednisone Hydroxychloroquine Azathioprine Mycophenolate Methotrexate Cyclophosphamide Leflunomide Cyclosporine No treatment |
71 (71%) 75 (75%) 24 (24%) 23 (23%) 8 (8%) 5 (5%) 2 (2%) 1 (1%) 9 (9%) |
COVID-19 background | |
Yes No |
39 (39%) 61 (61%) |
Hospitalization for COVID-19 | 3 (3%) |
SLE reactivation in the last 6 months (documented by rheumatologist physician) | 28 (28%) |
Data are n (%) or median (IQR).
*12 patients presented 2 or more comorbidities
†APS antiphospholipid syndrome
‡Juvenile idiopathic arthritis (1), avascular necrosis (1), primary biliary cirrhosis (1), diabetes (2), transverse myelitis (1), fibromyalgia (4), pulmonary fibrosis (2), glaucoma (2), asthma (1), aortic stenosis (1), hepatitis C (2), celiac disease (1), pregnancy (1)
ǂ70 patients had 2 or more systems affected by SLE
72 patients were taking 2 or more drugs